Results 41 to 50 of about 35,844 (248)

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Bone Healing Around Implants in Normal and Medically Compromised Conditions: Osteoporosis and Diabetes

Advanced Healthcare Materials, EarlyView.
xx xx. ABSTRACT Osseointegration of orthopedic and dental implants is influenced by local and systemic factors, including their physicochemical surface properties and the patient's overall health status. Titanium and its alloys have been a longstanding standard for bone implants due to their innate biocompatibility and mechanical properties.
Dainelys Guadarrama Bello, Fabio Variola, Antonio Nanci   +2 more
wiley   +1 more source

Activating the Osteoblastic USP26 Pathway Alleviates Multi‐Organ Fibrosis by Decreasing Insulin Resistance

Advanced Science, EarlyView.
The loss of Ubiquitin Specific Peptidase 26 (USP26) in osteoblasts results in decreased bone formation, as well as multi‐organ fibrosis associated with insulin resistance (IR). Mechanistically, the absence of USP26 reduces glycolysis and lactate accumulation, leading to decreased histone H3 lysine 18 lactylation (H3K18LA) in the promoter region of KH ...
Jiyuan Tang, Wenkai Ye, Liang He, Zhou Dan, Leilei Chang, Zijie You, Yuanyue Jiang, Guoqing Tang, Lianfu Deng, Changwei Li   +9 more
wiley   +1 more source

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [PDF]

, 2015
Purpose: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied.
A Lipton, Ada Braun, Alexander Paterson, Alison T. Stopeck, AM Brufsky, AO Hoff, AT Stopeck, CR Dunstan, D Amadori, Denise Yardley, F Saad, F Saad, Frank Kueppers, GA Block, Huei Wang, Ingo Diel, Janet E. Brown, Jean-Jacques Body, JJ Body, Jorge Arellano, K Fizazi, K Fizazi, Karim Fizazi, Katia Tonkin, L Gedmintas, Lawrence Karsh, LS Rosen, MG Kris, Michael Carducci, Miguel Martín, MR Smith, MR Smith, Neal Shore, NS Tchekmedyian, Paul Sieber, R Paparodis, RE Coleman, RG Russell, S Doshi, SL Ruggiero, ST Chang, Tapan Maniar, XGEVA® (denosumab) US Package Insert, Yasuhiro Fujiwara   +43 more
core   +1 more source

Rescuing Mitochondrial Dysfunction in Macrophages Prevents Osteonecrosis of the Jaw in Anti‐Resorptive Therapy

Advanced Science, EarlyView.
Schematic model showing the suggested mechanism that ZA induces classical activation of macrophages by impairing mitochondrial biofunction and inhibiting mitochondrial clearance to contribute to the pathological process of BRONJ. RAPA‐loaded nanoparticles ZDPR has shown potential in alleviating BRONJ lesions as well as treating osteoporosis or ...
Hang Zhang, Xin Shen, Haiyang Liu, Xinxi Yuan, Mumin Cao, Xuepeng Lv, Ziji Ling, Songsong Guo, Rongyao Xu, Xiang Li, Hongbing Jiang   +10 more
wiley   +1 more source

Adherence of denosumab treatment for low bone mineral density in Japanese people living with HIV: a retrospective observational study

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Long-term care issues, specifically metabolic bone disorders, are a concern for people living with human immunodeficiency virus (PLWH) who undergo life-long antiretroviral therapy (ART).
Yusuke Kunimoto, Ryosuke Matamura, Hiroshi Ikeda, Hiroto Horiguchi, Satoshi Fujii, Masayoshi Kobune, Masahide Fukudo, Takaki Toda   +7 more
doaj   +1 more source

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain [PDF]

, 2015
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in ...
Darbà, Josep, Kaskens, Lisette, Lothgren, Mickael, Sorio Vilela, Francesc   +3 more
core   +1 more source

Targeting the Hyperglycemic Pre‐Metastatic Niche to Prevent Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
Abstract The recent pioneering study by Ye et al. (Adv Sci. 2025;12(37):e0504924) provides compelling evidence that systemic hyperglycemia orchestrates a pre‐metastatic niche (PMN) in bone, promoting breast cancer metastasis and identifying Receptor for Advanced Glycation End‐products (RAGE) inhibition as a viable therapeutic strategy.
DuJiang Yang, Jiexiang Yang, GuoYou Wang
wiley   +1 more source

Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases

Journal of Bone Oncology
Background: Bone metastasis is a significant concern in advanced solid tumors, contributing to diminished patient survival and quality of life due to skeletal-related events (SREs). Denosumab (DMAB), a monoclonal antibody targeting the receptor activator
E. Mabrut, S. Mainbourg, J. Peron, D. Maillet, S. Dalle, C. Fontaine Delaruelle, E. Grolleau, P. Clezardin, E. Bonnelye, C.B. Confavreux, E. Massy   +10 more
doaj   +1 more source

Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review [PDF]

Archives of Endocrinology and Metabolism
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases.
Lisa Schmitt, Verena Theiler-Schwetz, Patrick Sadoghi, Christian Trummer, Stefan Pilz   +4 more
doaj   +1 more source